Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 OA vaccine in adults 18-49 at increased risk for RSV
NCT06389487Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2024
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
A Phase 3 trial of GSK3003899A in respiratory syncytial virus infection (RSV), sponsored by GSK. Started Apr 2024; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06389487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389487.